Clinical Stage Focus Keros Therapeutics is a clinical-stage biotech focusing on TGF-β signaling with lead program rinvatercept (KER-065) for Duchenne muscular dystrophy and ALS. This suggests BD opportunities with neuromuscular and neurodegenerative researchers, orphan drug incentives, and potential collaborations for proof-of-concept studies with pharma partners or CROs.

TGF-β Platform Broader platform in protein therapeutics addressing dysfunctional TGF-β signaling opens doors for collaborations across diseases; potential for platform licensing, protein engineering partnerships, and adjacent-indication exploration with pharma and academic partners.

Funding Signals With substantial funding support and a growing board, Keros signals readiness for co-development and research partnerships. Outreach opportunities exist with strategic investors and pharma companies seeking risk-sharing deals and development-stage services.

Conference Access Participation in major conferences provides scheduled access to potential partners; target outreach around upcoming events, with executive meetings, sponsorship options, and prepared collaboration briefs.

Regional Advantage Located in Lexington, MA within the Boston biotech cluster, Keros can leverage proximity to CROs, CMOs, and academic collaborations for preclinical to early-phase development, clinical trial support, and data services.